Prognostic value of pretreatment systemic inflammatory markers in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy

Abstract

The aim of this study was to explore the most powerful systemic inflammation marker of survival in locally advanced rectal cancer (LARC) patients and construct prognostic nomograms. A total of 472 LARC patients undergoing neoadjuvant chemoradiotherapy (NCRT) and radical surgery from 2011 to 2015 were included. The optimal cutoff points for the systemic immune-inflammation index (SII); and neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR), and monocyte-to-lymphocyte (MLR) ratios were calculated and determined by using the X-tile program. The cutoff values were 797.6. 2.3, 169.5, and 0.4, respectively. Cox regression analysis demonstrated that higher pathological TNM stage, the AJCC tumor regression grade, and the NLR level were significantly associated with increased overall survival and disease-free survival. High NLR level (≥ 2.3) was associated with higher pre-NCRT CA19-9 levels, lower hemoglobin, larger tumor size, and more lymph nodes retrieved (p = 0.012, p = 0.024, and p < 0.001; p < 0.001, respectively). High NRL scores were associated with poorer 5-year diseasefree survival and overall survival (p < 0.001, and p < 0.001, respectively). Predictive nomograms and time-independent receiver operating characteristic (ROC) curve that included the NLR score group were superior to those without NLR scores. Higher NLR scores (≥2 0.3) were associated with poorer DFS and OS in LARC patients. In addition, NLR was identified as the most effective marker for systemic inflammation, and the prognostic value was further confirmed by time-dependent ROC analysis. More intense adjuvant treatment could be considered for higher nLR score patients with LARc following ncRt. The standard of care for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (NCRT) followed by total mesorectal excision (TME). This strategy offers a higher probability of tumor downsizing and downstaging, increased tumor resectability, and better local tumor control 1-3. However, patients show a wide variation in responses to NCRT and thus, different oncological outcomes. Currently, it remains difficult to accurately predict treatment outcomes for LARC patients after NCRT. The identification of reliable biomarkers for the oncologic outcomes is important to assist in risk-adapted treatment strategies and subsequent surveillance. The systematic inflammatory response is involved in the development, progression, treatment response, and prognosis of many cancers, including prostate, breast, and colorectal cancers (CRC) 4-6. Accumulating evidence has demonstrated an association of systematic inflammation and resistance to radiotherapy and chemotherapy in CRC 7-9. The systematic inflammatory response can be reflected by hematological parameters, including the systemic immune-inflammation index (SII), the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and the monocyte-to-lymphocyte ratio (MLR). Several studies have revealed that the hematological inflammatory markers could be predictive markers for oncolo...

Construction of the Prediction Model for Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy Based on Pretreatment Tumor-Infiltrating Macrophage-Associated Biomarkers

“…Patient inclusion criteria, treatment protocol and follow up were as described in our previous study. 23 Briefly, preoperative long-course radiation consisted of a total dose of 45 Gy to the pelvis. Concurrent chemotherapy was initiated on the first day of radiotherapy using one of two chemotherapeutic regimens: 5FU plus oxaliplatin (FOLFOX) or capecitabine plus oxaliplatin (CapeOX).…”

Systemic Inflammation Response Index Is a Predictor of Poor Survival in Locally Advanced Nasopharyngeal Carcinoma: A Propensity Score Matching Study

“…Recently, an increasing number of studies have demonstrated the value of inflammatory response biomarkers as predictive markers for prognosis in cancers. It has been shown that the neutrophil-tolymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) can predict the prognosis in various types of cancers (7)(8)(9). The systemic inflammation response index (SIRI) is a new systemic inflammatory response biomarker based on peripheral blood cells counts, and it was demonstrated to be effective in predicting the prognosis of esophagogastric junction adenocarcinoma (10), esophageal cancer (11) and cervical cancer (12).…”

<p>Creation of a Novel Inflammation-Based Score for Operable Colorectal Cancer Patients</p>

“…Moreover, Xie et al 32 demonstrated that the high SII was independently correlated with unfavorable OS in patients with metastatic CRC. However, two clinical studies 33,34 investigating the prognostic significance of the SII in CRC patients receiving neoadjuvant chemoradiotherapy showed that the SII was not an independent predictor for OS or DFS. In addition, a recent study 7 with 408 CRC patients reported that SII was not associated with OS or DFS in multivariate Cox regression analyses.…”